Sign In
Buy CUE
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
04:10pm, Wednesday, 09'th Aug 2023
BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu
3 Biotech Stocks to Buy as Companies Ink Major Deals
06:40am, Thursday, 22'nd Jun 2023
With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy.
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
08:00am, Monday, 05'th Jun 2023
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu
3 Biotech Stocks Sitting on Huge-Upside Catalysts
06:19am, Friday, 26'th May 2023
Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
08:00am, Monday, 08'th May 2023
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul
7 High-Potential Penny Stocks in the Biotech Sector
01:56pm, Thursday, 04'th May 2023
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript
11:00pm, Tuesday, 21'st Mar 2023
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advis
Cue Biopharma to Host Business Update Call and Webcast
08:00am, Wednesday, 15'th Mar 2023
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and mod
Cue Biopharma to Present at Two February 2023 Scientific Conferences
08:00am, Wednesday, 01'st Feb 2023
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu
Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript
11:23pm, Monday, 14'th Nov 2022
Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Off
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
08:00am, Wednesday, 09'th Nov 2022
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul
Cue Biopharma to Host Business Update Call and Webcast
08:00am, Monday, 07'th Nov 2022
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call Transcript
08:13pm, Tuesday, 23'rd Aug 2022
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Offic
Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing
11:18am, Tuesday, 23'rd Aug 2022
Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
08:00am, Monday, 11'th Jul 2022
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul
